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Abstract 
 Topoisomerase inhibitors are in common use as chemotherapeutic agents although they 
can display reduced efficacy in chemotherapy-resistant tumours, which have inactivated DNA 
damage response genes, such as ATM and TP53. Here, we characterize the cellular response to 
the dual-acting agent, Alchemix (ALX), which is a modified anthraquinone that functions as a 
topoisomerase inhibitor as well as an alkylating agent. We show that ALX induces a robust DNA 
damage response at nano-molar concentrations and this is mediated primarily through ATR- and 
DNA-PK- but not ATM-dependent pathways, despite DNA double strand breaks being 
generated after prolonged exposure to the drug. Interestingly, exposure of epithelial tumour cell 
lines to ALX in vitro resulted in potent activation of the G2/M checkpoint, which after a 
prolonged arrest was bypassed allowing cells to progress into mitosis where they ultimately died 
by mitotic catastrophe. We also observed effective killing of lymphoid tumour cell lines in vitro 
following exposure to ALX, although, in contrast, this tended to occur via activation of a p53-
independent apoptotic pathway. Lastly, we validate the effectiveness of ALX as a 
chemotherapeutic agent in vivo by demonstrating its ability to cause a significant reduction in 
tumour cell growth, irrespective of TP53 status, using a mouse leukaemia xenograft model. 
Taken together, these data demonstrate that ALX, through its dual action as an alkylating agent 
and topoisomerase inhibitor, represents a novel anti-cancer agent that could be potentially used 
clinically to treat refractory or relapsed tumours, particularly those harbouring mutations in DNA 
damage response genes.  
 
 
 
 
 
 
Keywords Alchemix, ATM, ATR, p53, DNA damage, apoptosis, mitotic catastrophe, replication 
stress, Chk1, T-ALL. 
 
3	  	  
Introduction  
 
 Topoisomerase inhibitors are used as chemotherapeutic agents because of their potent 
ability to induce tumour cell death1-4. Typically, topoisomerase II (TOP2) inhibitors fall into two 
classes depending on their target1,5. The class I group (e.g. etoposide, doxorubicin, mitoxantrone) 
affects the catalytic activity of TOP2 during the DNA cleavage/ligation reaction resulting in 
stabilisation of the TOP2 cleavage complex in the presence of unligated DNA double strand 
breaks (DSBs), ultimately triggering apoptosis. The second class inhibits the catalytic activity of 
TOP2 before cleavage-complex formation and DSB generation and functions by reducing levels 
of chromosome-bound TOP2. As a consequence, since TOP2 is required to decatenate replicated 
DNA molecules before the onset of chromatid separation during mitosis, treatment with this type 
of TOP2 inhibitor (e.g. aclarubicin) induces cell death by mitotic catastrophe due to anaphase-
associated fragmentation of catenated chromatids6. 
 
 Whilst TOP2 inhibitors have been used relatively successfully as a mono-therapy, 
recently this approach has been largely superseded by combination therapies due to the ease with 
which tumour cells develop resistance7. Specifically, it has been shown that the acquisition of 
mutations in DNA damage response (DDR) genes, such as ATM and TP53, a reduction in the 
cellular pools of TOP2 protein or the over-expression of drug efflux pumps, are common 
underlying causes of tumours becoming refractory to TOP2 inhibitors8. Therefore, there is a 
clinical need for second-generation TOP2 inhibitors that can circumvent these mechanisms of 
drug resistance. Accordingly, a series of modified, anthraquinone-based compounds have been 
developed that combine the capability of class I TOP2 inhibitors to induce DSBs with the DNA 
damaging ability of alkylating agents9-11. The rationale for development of these multi-functional 
DNA damaging agents is that they should induce genetic damage to such an extent that it cannot 
be tolerated even in the presence of mutations that compromise specific DNA repair, checkpoint 
or apoptotic pathways. Of these compounds Alchemix (ALX) was demonstrated to have the 
most potent anti-tumour activity in vivo using a xenograft mouse model9. Furthermore, ALX was 
not affected by over-expression of the multi-drug resistance gene P-gp indicating that it may be a 
more effective chemotherapeutic agent for treatment of tumours that have developed resistance 
to non-covalent DNA binding anthraquinone-based drugs. Despite this, it is not known which 
DNA damage pathways are activated following ALX treatment and whether the inactivation of 
tumour suppressor genes that are important critical regulators of these pathways, such as ATM or 
TP53, could cause resistance. In this study we use a biochemical approach to determine the mode 
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of action of ALX to ascertain whether it could be potentially used clinically to treat tumours that 
have developed resistance to conventional chemotherapeutic agents. 
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Results 
Alchemix induces a marked ATR-dependent DNA damage response in tumour cells, 
independently of ATM and p53. 
 To understand how ALX derives its potent anti-tumour activity we initially exposed 
HeLa cells to a range of concentrations of the drug and examined the activation of the DDR after 
5 and 24 hours, using Western blotting, coupled with antibodies recognising known substrates of 
the PI-3-kinase-like kinases (PIKK), ATM and ATR. Phospho-ATM (S1981) was used a marker 
of ATM activation. Phospho-SMC1 (S966), Nbs1 (S343) and Chk1 (S345) were used as markers 
of cell cycle checkpoint activation. Lastly, phospho-RPA and γ-H2AX were used as markers of 
DNA damage. A dose of 10-100nM elicited a significant response; therefore, 50nM was used for 
most experiments (Fig. S1A, S1B). To confirm these observations and to determine whether p53 
status affected the cellular response to ALX, several cancer lines (described in Table S1) were 
treated with ALX (50nM) and the activation of DDR pathways was monitored. Whilst the 
kinetics of DNA damage-induced signalling varied somewhat between the individual cell lines, 
we repeatedly observed strong activation of the DDR suggesting that the anti-tumour activity of 
ALX is probably mediated through its ability to induce DNA damage (Fig.1A, 1B, 1C, S1C, 
S1D).  
 Unlike other anthraquinone-based drugs, such as doxorubicin and mitoxantrone, which 
induce DNA damage by inhibiting TOP2, ALX can also damage cellular DNA through its 
alkylating side chain10. To determine which activity of ALX is more important for activating the 
DDR, we exposed HeLa cells to ALX or a derivative (ZP275) that cannot alkylate DNA whilst 
retaining its ability to inhibit TOP2. Whereas both compounds could induce phosphorylation of 
known PIKK substrates, loss of the alkylating side chain severely attenuated the DDR, indicating 
that it is a combination of these two DNA damaging properties that is important for ALX activity 
(Fig.1C). Moreover, ALX treatment failed to induce the mono-ubiquitylation of PCNA, typically 
observed in cells exposed to compounds that alkylate DNA or agents that induce replication fork 
stalling (Fig.S2). This suggests that the mechanism underlying the DNA alkylation activity of 
ALX occurs in a manner distinct from other chemotherapeutics. 
 In contrast to the signalling induced by ionising radiation (IR) or UV, the relative 
contribution of the individual PIKKs to activation of specific DDR pathways following exposure 
to class 1 TOP2 inhibitors is less well understood. It has been previously reported that both ATM 
and ATR are activated in cells exposed to the TOP2 inhibitors etoposide or doxorubicin12,13. This 
is clinically important since ATM is commonly mutated in many tumour types. One potential 
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underlying reason for this is that these agents can induce both DNA DSBs as well as stalled 
replication forks, which activate ATM and ATR, respectively. 
 To ascertain whether ALX was capable of inducing DNA DSBs and activating an ATM-
dependent DDR, HeLa cells were treated with ALX over 24 hours. Cells were fixed and 
immunofluorescence microscopy used to monitor DSB formation. Despite H2AX being strongly 
phosphorylated early in response to ALX treatment (2h), only at later times (8-24h) were γ-
H2AX/53BP1 foci discernible, indicating that DSBs are only formed after prolonged exposure 
(Fig.2A, 2B). This observation was supported by carrying out pulse-field gel electrophoresis on 
these cells following exposure to varying doses of ALX (Fig.2C). However, from our 
preliminary analysis of the DDR induced by ALX in tumour cell lines, the low level of ATM 
S1981auto-phosphorylation suggested that, despite the ability of ALX to generate DSBs, ATM is 
not markedly activated (Fig. 1A, 1B). This is supported by the observation that ALX did not 
induce the phosphorylation of KAP1 or Chk2, two specific substrates of ATM (Fig.S3A). 
Furthermore, combining the ATM inhibitor with ALX did not significantly affect activation of 
the DDR (Fig.S3B, S4A, S4B, S4C).  
 Since TOP2 inhibitors also induce replication-associated DNA damage, this would 
suggest that ATR could play a role in activating the damage-induced signalling pathways. To 
determine the contribution of ATR, DLD1 cells, engineered to mimic the human Seckel 
Syndrome-associated hypomorphic ATR mutation and its ATR complemented counterpart 
(Fig.3A), were exposed to ALX and the DDR monitored. Consistent with a role for ATR in 
controlling the DNA damage response to ALX, compromising the level of ATR reduced 
phosphorylation of several DNA damage-regulated repair/checkpoint proteins; this was rescued 
by re-expression of ATR (Fig.3A). Consistent with this, depletion of Claspin, a protein required 
for ATR-dependent Chk1 activation, reduced ATR-dependent phosphorylation of Chk1, induced 
by ALX (Fig.S5). These observations indicate that, unlike other DNA intercalating TOP2 
inhibitors, ALX primarily elicits an ATR- but not ATM-dependent DDR, despite inducing DSBs.  
 Interestingly, the phosphorylation of H2AX and RPA2 in DLD1-Seckel cells was highly 
elevated following ALX treatment, compared to the complemented cells (Fig.3A). Whilst ATR 
phosphorylates H2AX following exposure of cells to agents that stall replication forks14, it is 
likely that the observed enhanced phosphorylation of H2AX signifies the induction of replication 
stress, DSB formation and activation of a redundant PIKK. Consistent with this, knock-in DLD1 
cells in which an activation-associated serine residue of Chk1 was mutated to alanine (S317A) 
exhibited a similarly exacerbated phosphorylation of H2AX/RPA2 response following exposure 
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to ALX (Fig.3B). This indicates that the ATR-Chk1 checkpoint pathway is not only required to 
signal activation of the DNA damage-induced intra-S phase checkpoint, but is also essential for 
stalled replication fork stability. Treatment of DLD1-Seckel cells with ALX and an ATM 
inhibitor did not alleviate the induced replication stress, suggesting that in the absence of ATR, 
ATM is playing only a minor role in signalling pathways induced following ALX-dependent 
replication fork collapse (Fig.3D, S6A). Based on this, it is likely that DNA-PK, which normally 
regulates repair of DSBs by NHEJ, also responds to DSBs induced during replication stress. It 
has been previously reported that DNA-PK undergoes auto-phosphorylation after the treatment 
of cells with genotoxic agents such as UV, hydroxyurea and the TOP1 inhibitor, 
camptothecin15,16. In addition, DNA-PK becomes rapidly activated following nucleotide 
depletion when Chk1 activity is compromised17. Consistent with this, we observed increasing 
DNA-PK activation following exposure of HeLa cells to ALX, suggesting that it may be 
involved in regulating the cellular response to this DNA damaging agent (Fig.3C). To determine 
whether DNA-PK was responsible for the elevated phosphorylation of H2AX and RPA in ALX-
treated DLD1-Seckel cells, we exposed these cells to ALX in the presence or absence of a DNA-
PK inhibitor (Fig.3D). Strikingly, we observed that the H2AX and RPA2 phosphorylation 
induced by ALX in these cells was completely suppressed by the DNA-PK inhibitor, indicating 
that DNA-PK functions redundantly with ATR (Fig.3D). Surprisingly, we observed a modest 
reduction in the phosphorylation of Nbs1, Chk1 and RPA2 in cells treated with ALX and the 
DNA-PK inhibitor (Fig.S6B), indicating that DNA-PK may also play a role in activating the cell 
cycle checkpoint pathway rather than just responding to replication-associated DSBs. 
 Taken together these data demonstrate that Alchemix induces a DNA damage response 
primarily mediated by ATR and DNA-PK, which requires its ability to inhibit the TOP2 
cleavage complex and to alkylate DNA. 
 
Alchemix requires both TOP2α  and TOP2β  to elicit a DNA damage response but not 
mismatch, Fanconi Anaemia or ubiquitin-dependent repair pathways. 
 To investigate which components of the damage response machinery, besides the ATR-
Claspin-Chk1 replication-stress pathway, were important for eliciting a DDR following exposure 
to ALX, siRNA and knockout cell lines were used. To ascertain if the DNA damage, particularly 
the DSBs, generated during ALX treatment largely depends on the presence of TOP2, cells were 
transfected with TOP2α or TOP2β directed siRNAs, exposed to ALX and the DDR examined 
(Fig.4). Loss of either TOP2α or TOP2β alone failed to alleviate ALX-induced DNA DSBs, 
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suggesting that ALX is probably capable of inhibiting multiple class II topoisomerases, not just 
TOP2α (Fig.4) as reported previously9. Consistent with this, siRNA-mediated knockdown of 
both TOP2α and TOP2β reduced ALX-induced RPA2 phosphorylation (and that of H2AX to a 
limited extent), indicating that ALX is capable of targeting both forms of TOP2 in vivo (Fig.4). 
However, knock down of TOP2α and/or TOP2β resulted in an elevated ATR-dependent 
checkpoint response following ALX treatment (Fig.4), suggesting that events, independent of 
TOP2 inhibition, cause DNA lesions that largely determine its capacity to stall replication forks 
and activate ATR. 
 The mismatch repair (MMR) pathway plays a key role in the response to DNA alkylating 
agents and is essential for activation of the ATR checkpoint pathway18,19. As the ability of ALX 
to activate the ATR-dependent DDR requires its capacity to alkylate DNA, it is conceivable that 
this requires the MMR pathway. However, depletion of MSH2, critical to the MMR machinery, 
exacerbated rather than reduced the ALX-induced cellular DDR, demonstrating that the MMR 
pathway is dispensable for ALX-induced ATR activation (Fig.S7A). This suggests that tumour 
cells with deficiencies in MMR could be hypersensitive to the killing effects of ALX as 
previously observed for other structurally related anthraquinone-based agents20,21.  
 To ascertain if the Fanconi Anaemia (FA) and the RNF8-dependent ubiquitin-dependent 
repair pathways21, were involved in co-ordinating the cellular response to ALX, cells with or 
without FANCF or depleted of RNF8 were exposed to ALX and the damage response 
determined. Compromising either the FA repair machinery or RNF8-dependent DNA damage-
induced ubiquitylation affected the ALX-induced DDR significantly, suggesting that loss of 
these tumour suppressor pathways is unlikely to cause ALX resistance (Fig.S7B, S7C). 
 
Exposure to low dose ALX leads to G2/M checkpoint arrest, checkpoint slippage-associated 
mitotic abnormalities and death by mitotic catastrophe. 
 Since TOP2 is critically involved in removing DNA supercoils resulting from DNA 
unwinding during replication and separating catenated sister chromatids prior to the onset of 
anaphase, it is likely that treating cells with ALX will have detrimental effects on progress 
through both S-phase and mitosis. To determine how the kinetics of the DDR correlated with 
transit through the cell cycle, HeLa cells were exposed to a low dose of ALX and samples 
analysed by FACS analysis. Consistent with the early activation of ATR-dependent checkpoint 
response, cells treated with ALX for 4-8h accumulated in S-phase (Fig.5A). In keeping with the 
late induction of DSBs and subsequent activation of a DNA-PK-dependent DDR, cells treated 
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with ALX for 24h accumulated in late-S/G2-phase of the cell cycle as judged by the elevated 
levels of Cyclins A/B and low levels of phosphorylated histone H3 (Fig.5A, 5B). However 
interestingly, a significant proportion of the cells bypassed the checkpoint and progressed into 
mitosis with unrepaired DNA damage, which resulted in the development of severe mitotic 
abnormalities, such as misaligned/fragmented chromosomes, anaphase-bridging and multi-polar 
spindles (Fig.5C).  
 To determine whether the accumulation of DNA damage in cells entering mitosis 
contributes to cell death, HeLa cells were treated with higher doses of ALX and harvested every 
24h for analysis by FACS, Western blotting and immunofluorescence microscopy. As a control, 
cells were also treated with cisplatin to induce cell death through classical apoptotic pathways. 
As expected, cisplatin induced cell death predominantly by apoptosis, seen as by PARP1 and 
Lamin B1 cleavage, proteolysis (activation) of Pro-caspase 3 and nuclear fragmentation (Fig.6A, 
6B). In contrast, although higher concentrations (up to 0.5µM) of ALX could induce a significant 
amount of cell death (Fig.6A), this was not associated with markers of apoptosis or autophagy, 
(Fig.6B, S8A), suggesting that these are not a major mode of cell death at these doses. A similar 
response was also seen in the p53 wt U2OS cell line as well as the p53-null H1299 cell line 
(Fig.S8B, S8C). However, it should be noted that PARP1 was consistently observed to be 
cleaved to a limited extent at early times in some cell lines following ALX exposure (Fig.6B). 
Despite this, we observed that ALX primarily induced cell death through a mechanism consistent 
with mitotic catastrophe/abortive mitosis, although a small proportion of the ALX-treated cells 
underwent apoptosis (Fig.6C, 6D). Interestingly, cells undergoing prolonged mitotic arrest can 
trigger a partial apoptotic response and induce p53, following slippage into the next G1 phase of 
the cell cycle23. In this respect, exposure to ALX can lead to the stabilisation of p53, although its 
ability to up-regulate downstream transcriptional targets, such as HDM2 and p21, appeared to be 
limited to later time following drug treatment, which coincided with the formation of DSBs and 
the appearance of abnormal mitotic cells (Fig.S8D). This could in part explain the apoptotic-like 
cell death we observed in cells expressing wt p53 following exposure to very high doses (>1µM) 
of ALX (Fig.7C, S9C). 
 
Induction of DNA damage and cell death following exposure to ALX is enhanced in cycling 
cells and can be exacerbated under conditions of replication stress. 
 Given that the primary DDR response following ALX treatment requires ATR and that 
ALX-induced loss of cell viability is predominantly mediated through mitotic catastrophe, this 
suggests that cycling cells would be predicted to be more responsive to ALX. To test this, 
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hTERT-immortalised RPE1 cells were synchronised in G0/G1 by serum starvation or left to 
cycle asynchronously, treated with ALX and the DDR examined. Consistent with a cell cycle-
dependency for ALX to induce a DDR, cells arrested in G0/G1 exhibited a highly attenuated 
ATR-dependent DNA damage response, with the expression of a number of the key regulatory 
effector molecules, such as Chk1, being down-regulated (Fig.7A). Consequently the arrested 
cells demonstrated an increased resistance to killing effects of ALX (Fig.7B, 7C). Again, as 
noted above, only at very high doses of ALX was cleavage of PARP1 and Lamin B1 observed. 
 
 It has been previously shown that pre-malignant cells commonly exhibit uncontrolled 
DNA replication that gives rise to elevated levels of DNA damage, which needs to be bypassed 
before a tumour can progress. This has been termed ‘replication stress’. Whilst a number of 
genetic and epigenetic factors have been implicated in inducing replication stress, the most 
closely studied of these is the activation of certain oncogenes. Over-expression of Cyclin E, 
commonly associated with many tumours, causes an increase in replication fork stalling and 
DSBs24,25. Since this hallmark of pre-malignant cells mildly mimics the cellular response to ALX 
we considered whether treatment of replication-stressed cells with ALX may exacerbate the 
cellular DDR. U2OS cells with either normal or significantly elevated levels of Cyclin E were 
exposed to ALX and the DDR monitored. Cells over-expressing Cyclin E exhibited an increased 
DDR, particularly the phosphorylation of RPA2 and H2AX, which coincided with the earlier 
generation of DSBs as judged by 53BP1 foci formation (Fig.8A, 8B). A similar exacerbation of 
the DDR was also observed when immortalised human fibroblasts were infected with a 
recombinant adenovirus expressing Cyclin E or induced to over-express mutant H-RasG12V and 
then exposed to ALX (Fig.S9A, S9B). Moreover, the increased replication stress induced by 
Cyclin E over-expression in U2OS cells resulted in an earlier onset of an apoptotic-like cell 
death following exposure to a very high dose of ALX (Fig.S9C). This supports the idea that 
ALX may have some specificity towards tumour cells with deregulated DNA replication and 
high levels of replication stress. 
 
ALX exhibits therapeutic potential against lymphoid tumours irrespective of TP53 status in 
vitro and in vivo. 
 Resistance to treatment is a feature of subsets of most tumour types and, in the case of 
lymphoid tumours, such as B and T cell ALL, is frequently associated with mutations in DDR 
genes such as ATM and TP53 or the up-regulation of multi-drug resistance gene expression26-28. 
While chemo-resistance is evident in some treatment-naive tumours, genetic changes associated 
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with chemotherapy resistance are frequently acquired during prolonged exposure to cytotoxic 
agents29,30. In ALL, around 10% of paediatric patients and over 50% of adult patients fail to 
undergo complete remission or experience relapse following treatment. As mutations in TP53 
play a major role in high risk and relapsed ALL disease30-32 ALX might represent a useful 
therapeutic approach for these tumours. To investigate this, we tested the efficacy of ALX in 
vivo against primary and immortalised tumour cells with different p53 status (Fig.9A). These 
included a primary paediatric T-ALL sample (BCH-505) and the Molt4 T-ALL cell line, both of 
which have wt TP53, and the TP53 mutant T-ALL cell lines CCRF-CEM and Jurkat. The 
primary T-ALL BCH-505 was engrafted into NOG mice, such that cells disseminated to the 
lymphoid organs within 4 weeks. The T-ALL tumour cell lines were injected subcutaneously to 
enable analysis of visible tumours. Following two doses of ALX, we observed a marked 
reduction in subcutaneous tumour size for the cell lines as well as the spleen weights (an 
indicator of tumour engraftment) and human CD45 tumour load in the primary T-ALL BCH-505 
treated animals (Fig.9B, 9C). This indicates no apparent difference in the sensitivities of the 
TP53 wt and mutant tumours to ALX in vivo. 
 To confirm the mechanism of killing, Western blotting was employed to establish that 
ALX induced a DDR in the T-ALL cell lines (Fig.9A). Significant cell death was observed in all 
ALL cell lines in response to low dose ALX (summarized in Table S2) with considerable 
activation of apoptotic pathways as judged by the rapid cleavage of PARP1, LaminB1 and Pro-
caspase 3 in (Fig.S10). This indicates that ALX can induce tumour cell death through multiple 
different pathways depending on the cell type treated and the dose used. 
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Discussion 
Most current empirically-based chemotherapeutic agents kill tumour cells by inducing 
irreparable genomic damage, leading to apoptosis. However, even complex and intensive 
combinations of cytotoxic agents fail to overcome the evolution and selection of treatment-
induced sub-clones in some tumours, which leads to the outgrowth of refractory disease29,30,34,35. 
Such sub-clones frequently arise following mutations in mediators of DNA damage-induced cell 
death, such as TP53. One major problem in combating treatment resistance is that our 
understanding of the mechanism of action of many chemotherapeutic agents currently used is 
limited.  
Here we demonstrate that ALX can induce a two-stage DNA damage response that 
requires its ability to inhibit TOP2 and to alkylate DNA. Treatment of tumour lines with ALX 
induces replication damage, which in turn activates an ATR-dependent DDR and culminates in 
cells accumulating in G2-phase. It is likely that enzymatic processing or spontaneous collapse of 
stalled/aberrant replication forks results in the generation of DNA DSBs that triggers DNA-PK 
activation (summarized in Fig.10). This DDR can be initiated in the absence of known tumour 
suppressor genes, such as ATM, TP53, FANCF and MSH2, the mutation of which have been 
associated with treatment resistance. Moreover, despite a requirement for ATR and Chk1 to 
mediate activation of the ALX-induced cell cycle checkpoint, loss of this pathway exacerbates 
the formation of DSBs, indicating a role for ATR in preventing stalled replication fork collapse 
caused by exposure to ALX. 
The DNA damage induced by ALX requires the presence of TOP2. However, in contrast 
to previously published data indicating that ALX specifically inhibits TOP2α, the depletion of 
both TOP2 isoforms was required to reduce ALX-induced phosphorylation of H2AX. Based on 
this observation, it is conceivable that resistance to ALX could develop by reducing cellular 
pools of TOP2α and β. Interestingly however, depletion of TOP2α and β does not affect 
activation of the ATR-dependent checkpoint response following exposure to ALX, indicating 
that suppression of cell replication and division could still be achieved with reduced TOP2 
expression. Therefore, it is tempting to speculate that this is dependent upon its DNA alkylation 
function, which we have demonstrated is important for the ability of ALX to induce a DDR. 
Given the complex nature of ALX’s ability to produce a variety of different deleterious 
DNA lesions, it is unsurprising that the mechanisms by which it induces cell death are 
complicated. Despite ALX treatment causing cell cycle arrest in S and G2 phases of the cycle, it 
is clear that checkpoint slippage can occur and cells enter mitosis, most probably with unrepaired 
DNA DSBs, under-replicated DNA and/or catenated sister chromatids. As a result a major cause 
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of cell death in epithelial tumour lines is through mitotic catastrophe after treatment with low 
doses of ALX. On this basis, since mitotic catastrophe does not require a functional ATM-p53 
axis, tumour cells normally resistant to most conventional chemotherapeutic agents, due to 
mutations in this pathway, should be sensitive to killing by ALX. However, we did observe that 
ALX, at low dose, could induce apoptosis in HeLa cells, albeit to a low level, as judged by the 
partial PARP1 cleavage. Although it should be noted that this did not coincide with Pro-caspase 
3 nor Lamin B1 cleavage indicating the possible activation of a non-canonical apoptotic pathway. 
In this respect, it has been observed that cells undergoing a prolonged block in mitosis can 
induce a p53-dependent apoptotic mode of cell death following slippage into the subsequent G1 
phase of the cell cycle23. Consistent with this, we observed that ALX can induce the stabilisation 
of p53, although it only appeared to be transcriptionally competent at later times during the DDR, 
probably linked with the generation of DSBs. It is therefore conceivable that ALX can induce 
cell death through either mitotic catastrophe and/or apoptosis. In keeping with this, ALX 
robustly induces apoptosis in the lymphoid tumour cells although this did not appear to require 
p53. Taken together our observations indicate that ALX can induce cell death through multiple 
different pathways in a variety of cell types independently of key regulators of the DDR known 
to be associated with treatment resistance.  
 Since ATM and TP53 are commonly mutated in lymphoid tumours and this is associated 
with increased disease progression and treatment resistance, to ascertain whether ALX could be 
used as an effective chemotherapeutic agent in vivo to target these tumours we used T-ALL 
xenografts as a model for treating lymphoid tumour cells with and without TP53 mutations. In 
vitro, ALX was able to induce a robust DDR and a significant amount of cell death in all three T-
ALL tumour cell lines to a similar degree irrespective of TP53 status. Consistent with this, we 
observed that ALX was able to significantly reduce the tumour load in mice engrafted with any 
of three T-ALL cell lines tested. Moreover, similar observations were seen in mice engrafted 
with a patient-derived, primary T-ALL tumour. 
 In summary, we propose that ALX, through its ability to activate different pathways of 
the DDR and to induce cell death by mitotic catastrophe and/or apoptosis, represents a novel 
therapeutic agent with a clinical potential to treat resistant/relapsed tumours harbouring 
mutations in DDR genes. 
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Materials and Methods 
Cell lines 
The human cell lines used in this study are detailed in Supplementary Table S1.  
 
Drug treatments 
Alchemix9 and ZP275 were dissolved in DMSO and routinely added to cells to give a final 
concentration of 50nM in the culture medium. For experiments examining cell killing, ALX 
concentrations of 150 and 500nM were used. Cisplatin (EBEWE Pharma) was used at a 
concentration of 10µg/ml.  The ATM inhibitors, KU-55933 (Merck) or KU60019 (Tocris) were 
used at 10µM, the DNA-PK inhibitor, NU7441 (Tocris) was used at 10µM and the ATR 
inhibitor, VE-821 (Selleckchem) was used at 5µM. 4-hydroxy-tamoxifen (Sigma) was used at 
334nM. 
 
siRNA treatment. 
Smart-pools (Thermo) of siRNA were used to reduce expression of MSH2, Mre11, TOP2α and 
TOP2β. siRNA (0.4nmoles) was transfected into cells (4x105) using Oligofectamine (Invitrogen). 
Experiments were performed 72 hours later. 
 
Quantification of autophagy  
HEK293A cells, expressing GFP-LC333 were cultured in DMEM/10% FCS and this served as 
full media. Earle's balanced salt solution (EBSS) was starvation medium. 293/GFP-LC3 cells 
were seeded onto glass coverslips, 24h later full media was replenished in the presence or 
absence of ALX and the cells left for 24h. Starvation was induced in EBSS for the final 4 hours 
where indicated. Cells were fixed with paraformaldehyde and mounted on glass slides. Multiple 
random fields were collected and GFP-LC3-labelled structures counted.  
Western blotting and antibodies. 
Cell pellets were solubilized in 9M urea, 50mM Tris HCl pH7.4, 0.15M β mercapto-ethanol and 
proteins extracted before being fractionated on polyacrylamide gels run in 0.1M Bicine, 0.1M 
Tris, 0.1% SDS. Antibodies used in this study are listed in Supplementary Table S3. 
  
FACS analysis. 
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FACS analysis was used to determine the percentage of dead cells after drug treatments. Cells 
were harvested and stored in 70% ethanol at -20ºC. They were then suspended in propidium 
iodide (25µg/ml), RNAse (0.1mg/ml) at 37°C. DNA profiles were obtained using either an XL-
MCL or Accuri flow cytometer. Proportions of cells in different phases of the cell cycle were 
calculated using WinMDI version 2.9. 
 
Immunofluorescence microscopy. 
Immunofluorescence was carried out as previously described36. 
 
Pulse-field Gel Electrophoresis (PFGE) 
PFGE was carried out as previously described37. 
 
In vivo xenograft models: lymphocytic leukaemia 
All procedures complied with U.K. home office guidelines.  Primary leukemic material was 
obtained with ethical consent from Birmingham Children’s Hospital (CCLG 08/H0405/22, 
08/H1208/4 and 09/H1010/75).  The T-ALL cell lines, Jurkat, CEM and Molt4, were injected 
subcutaneously into the flanks of NOG mice (3x106 cells/mouse). When tumours became 
palpable in >65% of mice, animals were randomized into two groups (n=6 per group). Two 
weekly doses of ALX (8mg/kg) were administered via intra-peritoneal (IP) injection (days 0 and 
7) following initiation of treatment to the test group while the control group received ‘vehicle’ 
(1% DMSO/PBS) alone. During treatment tumour volumes were determined for up to 16 days or 
until the control tumours reached the maximum permitted volume. For the primary T-ALL 
sample (BCH-505), 1x106 cells/mouse were injected via the lateral tail vein into NOG mice and 
the peripheral blood sampled weekly and stained using anti-human CD45 antibody.  When the 
percentage of human CD45 cells in the blood reached >1%, mice were randomized into two 
groups (n=6/group) and received either two single weekly doses of ALX (8mg/kg) or ‘vehicle’.  
When the proportion of human CD45 cells reached >25% in the blood in the control group, 
animals were sacrificed. Harvested spleens were weighed. Single cell suspensions were obtained 
from the spleens and bone marrow and stained for the presence of human CD45 to determine the 
final human tumour load.  
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Figure legends. 
Figure 1. ALX induces a DNA damage response in tumour cell lines. U2OS (A), H1299 (B) and 
HeLa (C) cells were treated with ALX (50nM) and harvested at the times shown. Protein 
phosphorylation was visualised by Western blotting using the antibodies shown. HeLa cells (C) 
were also treated with the ALX derivative, ZP275, which fails to alkylate DNA, as shown. 
 
Figure 2. DNA double strand breaks are generated only after prolonged exposure to ALX. (A), 
HeLa cells were exposed to ALX and processed for immunofluorescence microscopy at the 
indicated times post-treatment. Cells were stained for γH2AX and 53BP1. Nuclear DNA was 
visualized with DAPI. (B), the proportion of γH2AX and 53BP1 foci (of various dimensions and 
intensities) formed was estimated on the basis of the representative images shown in the right-
hand panel. The relative percentage of cells in each category at 24 hours after ALX treatment is 
shown in the left-hand panel. The type V γ-H2AX/53BP1 staining pattern is typical of 
undamaged cells in S-phase. (C), Pulse-field gel electrophoresis was used to detect the presence 
of DNA double strand breaks (DSBs) in cells that were treated with increasing concentrations of 
ALX for 24h. As a positive control for the presence of DSBs, cells were irradiated with 30Gy of 
ionising radiation (IR) and harvested 2h post-irradiation. 
 
Figure 3. ALX induces a DNA damage response mediated by ATR and DNA-PK. (A), DLD1-
Seckel cells and DLD1-Seckel cells complemented with ATR were exposed to ALX (50nM). 
Cells were harvested at the times shown. Protein phosphorylation was determined by Western 
blotting using the antibodies shown. (B), as (A) except that DLD1 cells in which Chk1 S317 had 
been mutated to alanine were used. (C), HeLa cells were treated with ALX for the times shown. 
The phosphorylation of DNA-PKcs S2056 was determined by Western blotting. (D), DLD1-Seckel 
cells were treated with ALX for the times shown in the presence and absence of either the ATM 
inhibitor, KU60019, (10µM) or DNA-PK inhibitor, NU7441, (10µM). Protein phosphorylation 
was determined by Western blotting using the antibodies shown. 
 
Figure 4. TOP2α and TOP2β are necessary for an ALX-induced DNA damage response. HeLa 
cells were depleted of TOP2α and/or TOP2β with siRNA and then exposed to ALX (50nM) for 
the times shown. Protein expression and level of protein phosphorylation were determined by 
Western blotting as shown. 
 
18	  	  
Figure 5. Cells bypassing the ALX-induced G2/M checkpoint exhibit mitotic abnormalities. (A), 
HeLa cells were treated with ALX (50nM) and analysed by FACS. Cell cycle profiles obtained 
up to 24 hours are shown, together with the percentage of cells in the different stages of the cycle 
(inset). (B), HeLa cells treated with ALX (50nM) for 24 hours were Western blotted for the 
proteins shown. (C), HeLa cells were treated with ALX (50nM) for 24 hours and then examined 
by immunofluorescence microscopy. The number of cells in different stages of mitosis as well as 
those exhibit mitotic abnormalities was determined (left-hand panel). The percentage of cells 
with different mitotic abnormalities was determined (central panel). A minimum of 500 mitotic 
cells were counted per experiment. Examples of mitotic abnormalities seen in ALX-treated cells 
are shown in the right-hand panel. 
 
Figure 6. Low dose ALX induces cell death in epithelial cells primarily by mitotic catastrophe 
and not by apoptosis. (A), HeLa cells were treated with ALX (500nM) or cisplatin (10µg/ml) for 
the times shown and then analysed by FACS. The percentage of cells in each stage of the cell 
cycle and in the sub-G1 population (taken as dead cells) is inset. (B), HeLa cells were treated 
with ALX (150nM or 500nM) or cisplatin (10µg/ml) for the times shown. After harvesting, 
lysates were Western blotted for PARP1, Lamin B1 and Pro-caspase 3. (C), HeLa cells were 
seeded on microscope slides and treated with ALX (150nM) or cisplatin (5µg/ml) for 24 hours. 
Cells were processed for immunofluorescence microscopy using antibodies against histone H3 
phospho-serine S10, γH2AX, and Lamin B1. Nuclear DNA was stained with DAPI. 
Representative images showing staining in cells typical of apoptosis or mitotic catastrophe are 
presented. The percentage of cells undergoing each form of cell death is shown graphically in 
(D). A minimum of 500 mitotic cells were counted per experiment. 
 
Figure 7. Non-cycling cells have a significantly reduced ALX-induced DNA damage response 
compared to their cycling counterparts. hTERT immortalised RPE1 cells were either arrested in 
G0/G1 by serum starvation or left to cycle asynchronously. (A), Cells were treated with ALX 
(50nM) as shown and subjected to Western blotting using the antibodies shown (upper panel). 
FACS analysis of the asynchronous and synchronised RPE1 cells in the absence of ALX 
treatment is shown in the lower panel. (B), Cycling and non-cycling RPE1 cells were treated 
with ALX (150nM or 500nM) or cisplatin (10µg/ml) for 48 hours. They were then analysed by 
FACS and the sub G1 peak taken as dead cells. (C), Cycling and non-cycling RPE1 cells were 
treated with ALX (1µM or 3µM) or cisplatin (30µg/ml). Cells were harvested at the times shown 
and Western blotted with antibodies against PARP1, Pro-caspase3, Lamin B1 and p53. 
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Figure 8. Replication stress enhances the ALX-induced DNA damage response. (A), U2OS cells 
with normal (+Tetracycline) or elevated expression of Cyclin E (-Tetracycline) were treated with 
ALX (50nM). Cells were harvested and protein expression determined by Western blotting using 
the antibodies shown. (B), U2OS cells, with normal or elevated expression of Cyclin E, were 
treated with ALX (50nM) for the times shown and processed for immunofluorescence 
microscopy. Upper panel shows cells stained with antibodies against γH2AX and 53BP1. 
Nuclear DNA was stained with DAPI. The lower panels show the percentage of cells with 
greater or less than five 53BP1 foci per cell. 
 
Figure 9. The effect of ALX on leukaemic cells in vitro and in vivo. (A), ALX induces a DNA 
damage response in T-ALL cell lines, Jurkat, CEM and MOLT4 cells were treated with ALX 
(50nM) and harvested at the times shown. Western blotting of lysates with the antibodies shown 
was used to visualize protein phosphorylation. (B), ALX reduces the tumour load in mice with 
tumours derived from T-ALL cell lines. Cells were injected into NOG mice, which were then 
treated (as indicated by arrows) with vehicle or ALX (5mg/kg) as described. Tumour volume 
was measured. (C), ALX reduces tumour load in mice engrafted with paediatric T-ALL cells, 
BCH-505. The histograms show the relative size of the spleens in mice treated with ALX or 
controls at the time of death as well as the expression of human CD45 (*, p<0.05; **, p<0.005, 
***, p<0.0005). 
 
Figure 10. A possible mechanism for the mode of action of ALX. 
ALX inhibits TOP2 complexes present at a replication fork that results in the generation of a 
DNA double strand break (DSB). The binding of ALX to TOP2 may promote its ability to 
alkylate DNA in close proximity to a replication fork. The combination of a DSB and localised 
DNA alkylation is likely to result in fork stalling and activation of the ATR-dependent cell cycle 
checkpoint pathway. Following a prolonged growth arrest, a significant proportion of cells 
bypass the checkpoint and either enter into mitosis with unrepaired DNA damage that triggers 
mitotic catastrophe or activate p53-independent apoptosis. In cells lacking an intact ATR-Chk1 
pathway or undergoing replication stress, an increased number of stalled/damaged replication 
forks collapse resulting in the activation DNA-PK. It is possible that attempted repair of a 
collapsed replication fork or TOP2-associated DSB by DNA-PK-dependent repair pathways 
produces deleterious DNA structures that exacerbate abortive mitosis.  
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Legends to supplementary figures. 
Figure S1. Increasing concentrations of ALX induces an increased DNA damage response. 
Increasing concentrations of ALX were added to H1299 cells, which were harvested after 5 
hours (A) and 24 hours (B). The concentrations of ALX used are shown at the top of the figure. 
(C), DLD-1 cells were treated with ALX (50nM) and harvested at the times shown. (D), as (C) 
except that HCT116 cells were used. In all cases the extent of protein phosphorylation was 
determined by Western blotting using the antibodies shown. 
 
Figure S2. ALX does not induce PCNA mono-ubiquitylation. HeLa cells were treated with ALX 
and harvested at the times shown. Cells were also UV-irradiated (20J/m2) or treated with 
etoposide (1µM for 8h.). Cells were harvested and the expression of PCNA determined by 
Western blotting. Multiple exposures of the Western blot are shown. 
 
Figure S3. ALX does not activate the ATM pathway. (A), HeLa cells were treated with ALX 
(50nM) for the times shown. Western blotting was used to assess the phosphorylation of KAP-1 
and Chk2. (B), HeLa cells were treated with ALX (50nM) in the presence and absence of the 
ATM inhibitor, KU-55933 (10µM).  Cells were harvested at the times shown and the extent of 
protein phosphorylation determined by Western blotting. The efficacy of the ATM inhibitor is 
shown in the right-hand panel.  
 
Figure S4. ATM is not activated by ALX. (A), HeLa cells were treated with control or ATM 
inhibitor KU-55933 (10µM) for 24 hours. They were then treated with ALX (50nM) for the 
times shown, fixed and processed for immunofluorescence microscopy using antibodies against 
γH2AX and 53BP1. (B), Different γH2AX and 53BP1 staining patterns designated Type I to V 
in (C). (C), upper panel, γH2AX and 53BP1 staining seen in cells after treatment with the ATM 
inhibitor but before addition of ALX; lower panel, γH2AX and 53BP1 staining seen in cells 
treated with ALX for 24 hours. 
 
Figure S5. Claspin expression is required for the full activation of the DNA damage response by 
ALX. U2OS-shCLSPN cells were treated with doxycycline for 48 hours to reduce Claspin 
expression. Cells were then treated with ALX (50nM) and harvested at the times shown. The 
extent of protein phosphorylation was determined by Western blotting. 
 
21	  	  
Figure S6. The DNA-PK but not ATM pathway is activated by ALX in the absence of ATR. (A), 
DLD1-Seckel cells and DLD1-Seckel cells in the presence of the ATM inhibitor, KU-55933 
(10µM) were treated with ALX (50nM) and harvested at the times shown. The extent of protein 
phosphorylation was determined by Western blotting. Control irradiated cells are shown in the 
left-hand lanes to verify the activity of the ATM inhibitor. (B), HeLa cells were treated with 
50nM ALX in the presence of an ATR inhibitor (5µM) and/or DNA-PK inhibitor (10µM) for the 
times indicated. The extent of protein phosphorylation was determined by Western blotting. 
 
Figure S7. MSH2, FANCF and RNF8 are not involved in the cellular response to ALX. (A), 
HeLa cells were treated with control siRNA or siRNA targeted to MSH2. After 72 hours ALX 
(50nM) was added to the cells, which were then harvested at the times shown. (B), 2008 cells 
transfected with a control vector or a vector expressing FANCF were treated with ALX (50nM) 
and then harvested at the times shown. The FANCF status of the 2008 cells has been previously 
verified elsewhere38. (C), U2OS cells expressing an inducible RNF8 shRNA were treated with 
doxycycline for 48 hours and then treated with ALX (50nM). Cells were harvested at the times 
shown. In all cases protein phosphorylation and expression were determined by Western blotting. 
 
Figure S8. Low dose ALX does not induce autophagy or apoptosis in tumour epithelial cells, 
although it induces p53 expression. (A), 293 cells stably expressing the GFP-LC3 fusion protein 
were treated with doses of ALX as shown or serum starved for 4 hours. GFP-LC3 puncta were 
counted. 293 cells on full medium or serum starved were used as negative and positive controls, 
respectively. (B), U2OS and (C), H1299 cells were treated with ALX (150nM or 500nM) or 
cisplatin (10µg/ml) for the times shown. Protein expression was determined by Western blotting. 
(D), U2OS cells were treated with ALX (50nM) for the times shown. Protein expression was 
determined by Western blotting. 
 
Figure S9. Oncogene-induced replication stress exacerbates the DDR activated by ALX. (A), 
hTert-immortalised human fibroblasts were infected with either an empty adenovirus (Ad-Con) 
or adenovirus expressing Cyclin E (Ad-CycE). The cells were treated with 50nM ALX 48h post-
infection for the times indicated and the DDR was monitored by Western blotting. (B), hTert-
immortalised BJ skin fibroblasts expressing inducible mutant H-Ras (G12V) were either mock 
treated or treated with 334nM 4-hydroxy-tamoxifen (4-OHT) for 48h and then exposed to 50nM 
ALX for the times indicated. Activation of the DDR was monitored by Western blotting using 
the antibodies indicated. (C), U2OS cells in the presence or absence of tetracycline were exposed 
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to 3µM ALX for the time indicated and the harvested. Western blot analysis was used to monitor 
the induction of cell death. 
 
Figure S10. ALX induces apoptosis in T-ALL cell lines. Jurkat, CCRF-CEM and MOLT4 cells 
were treated with ALX (150nM or 500nM) or cisplatin (10µg/ml) for the times shown. Protein 
expression was determined by Western blotting as shown.  
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